

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Letermovir Liquid Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : 199 Wenhai North Road  
HEDA, Hangzhou - Zhejiang Province - CHINA 310018

Telephone : +1-908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

### 2. HAZARDS IDENTIFICATION

#### Emergency Overview

Appearance	: liquid
Colour	: clear
Odour	: odourless

Not a hazardous substance or mixture.

#### GHS Classification

|| Not a hazardous substance or mixture.

#### GHS label elements

|| No hazard pictogram, no signal word, no hazard statement(s), no precautionary statement(s) required.

#### Physical and chemical hazards

Not classified based on available information.

#### Health hazards

Not classified based on available information.

#### Environmental hazards

Not classified based on available information.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

### Other hazards which do not result in classification

None known.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

#### Components

Chemical name	CAS-No.	Concentration (% w/w)
Letermovir	917389-32-3	>= 1 -< 2.5

### 4. FIRST AID MEASURES

General advice	: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	: If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	: Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	: None known.
Protection of first-aiders	: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
Notes to physician	: Treat symptomatically and supportively.

### 5. FIREFIGHTING MEASURES

Suitable extinguishing media	: Water spray Alcohol-resistant foam Carbon dioxide (CO <sub>2</sub> ) Dry chemical
Unsuitable extinguishing media	: None known.
Specific hazards during fire-fighting	: Exposure to combustion products may be a hazard to health.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

Hazardous combustion products : Carbon oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 7. HANDLING AND STORAGE

#### Handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Take care to prevent spills, waste and minimize release to the environment.

Avoidance of contact : Oxidizing agents

**Storage**

Conditions for safe storage : Keep in properly labelled containers.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

Packaging material : Unsuitable material: None known.

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Letermovir	917389-32-3	TWA	0.4 mg/m3 (OEB 2)	Internal

**Engineering measures** : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Laboratory operations do not require special containment.

#### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

Hand protection

Material : Chemical-resistant gloves

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the work-

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

ing place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	: liquid
Colour	: clear
Odour	: odourless
Odour Threshold	: No data available
pH	: 7.5
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flash point	: No data available
Evaporation rate	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Vapour pressure	: No data available
Relative vapour density	: No data available
Relative density	: No data available
Density	: No data available
Solubility(ies) Water solubility	: No data available
Partition coefficient: n-	: Not applicable

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics

Particle size : Not applicable

### 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation  
Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

#### Components:

##### Letermovir:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg  
LD50 (Mouse): > 2,000 mg/kg

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Letermovir:

||Remarks : No data available

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Letermovir:

||Remarks : No data available

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### Letermovir:

||Remarks : No data available

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Letermovir:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES)
	Result: negative
	Test Type: Chromosome aberration test in vitro
	Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
	Species: Mouse
	Application Route: Intraperitoneal injection
	Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

### Carcinogenicity

Not classified based on available information.

### Reproductive toxicity

Not classified based on available information.

### Components:

#### Letermovir:

Effects on fertility	: Test Type: Fertility/early embryonic development Species: Rat, female Application Route: Oral Fertility: NOAEL: 240 mg/kg body weight Result: No effects on fertility  Test Type: Fertility/early embryonic development Species: Rat, male Application Route: Oral Fertility: LOAEL: 180 mg/kg body weight Result: No effects on fertility Remarks: The significance of these findings for humans is not certain.  Test Type: Fertility/early embryonic development Species: Monkey, male Application Route: Oral Fertility: NOAEL: 240 mg/kg body weight Result: No effects on fertility
Effects on foetal development	: Test Type: Embryo-foetal development Species: Rat Developmental Toxicity: LOAEL: 250 mg/kg body weight Result: Embryo-foetal toxicity Remarks: Maternal toxicity observed.  Test Type: Embryo-foetal development Species: Rabbit Developmental Toxicity: LOAEL: 225 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed., Abortion Remarks: Maternal toxicity observed.
Reproductive toxicity - Assessment	: Some evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.



# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

### Components:

#### Letermovir:

Exposure routes	: Ingestion
Target Organs	: Liver, spleen, Blood
Assessment	: May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

#### Letermovir:

Species	: Mouse
NOAEL	: 40 mg/kg
LOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 13 Weeks
Target Organs	: Liver, spleen

Species	: Rat
NOAEL	: 150 mg/kg
Application Route	: Oral
Exposure time	: 26 Weeks
Remarks	: No significant adverse effects were reported

Species	: Monkey
NOAEL	: 100 mg/kg
LOAEL	: 200 - 250 mg/kg
Application Route	: Oral
Exposure time	: 39 Weeks
Target Organs	: Kidney

Species	: Rat
NOAEL	: 60 mg/kg
LOAEL	: 180 mg/kg
Exposure time	: 13 Weeks
Target Organs	: Testis, Blood, Liver, spleen, Immune system

Species	: Monkey
NOAEL	: 30 mg/kg
LOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 4 Weeks
Target Organs	: Blood

### Aspiration toxicity

Not classified based on available information.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

### Experience with human exposure

#### Components:

##### Letermovir:

Ingestion	: Symptoms: Diarrhoea, Nausea, Vomiting, Headache, Dizziness, Fatigue, Back pain, Oedema, Rash, muscle pain
-----------	---

## 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### Letermovir:

Toxicity to fish	: LC50 (Menidia beryllina (Silverside)): > 100 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Americamysis): 16 mg/l Exposure time: 96 h  EC50 (Daphnia magna (Water flea)): > 100 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 8.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility  NOEC (Pseudokirchneriella subcapitata (green algae)): 8.8 mg/l Exposure time: 72 h Method: OECD Test Guideline 201 Remarks: No toxicity at the limit of solubility
Toxicity to fish (Chronic toxicity)	: NOEC (Pimephales promelas (fathead minnow)): 1 mg/l Exposure time: 32 d Method: OECD Test Guideline 210 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	: NOEC (Daphnia magna (Water flea)): 1.2 mg/l Exposure time: 21 d Method: OECD Test Guideline 211
Toxicity to microorganisms	: EC50: > 972 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

NOEC: 29.6 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

### Persistence and degradability

#### Components:

##### Letermovir:

Biodegradability : Result: rapidly degradable  
Biodegradation: 50 %  
Exposure time: 6.7 d

### Bioaccumulative potential

#### Components:

##### Letermovir:

Partition coefficient: n-octanol/water : log Pow: 2.29

### Mobility in soil

#### Components:

##### Letermovir:

Distribution among environmental compartments : log Koc: 3.46

### Other adverse effects

No data available

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Environmentally hazardous : no

### IATA-DGR

UN/ID No. : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Packing instruction (cargo aircraft) : Not applicable  
Packing instruction (passenger aircraft) : Not applicable

### IMDG-Code

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
EmS Code : Not applicable  
Marine pollutant : no

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### GB 6944/12268

UN number : Not applicable  
Proper shipping name : Not applicable  
Class : Not applicable  
Subsidiary risk : Not applicable  
Packing group : Not applicable  
Labels : Not applicable  
Marine pollutant : no

### Special precautions for user

Not applicable

## 15. REGULATORY INFORMATION

### National regulatory information

#### Law on the Prevention and Control of Occupational Diseases

#### Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the catalogue of hazardous chemicals and it does not meet the definition of haz-

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

ardous chemicals and its principles  
of determination.

Identification of Major Hazard Installations for Hazardous Chemicals (GB 18218) : Not listed

Hazardous Chemicals for Priority Management under SAWS : Not listed

Catalogue of Specially Controlled Hazardous Chemicals : Not listed

List of Explosive Precursors : Not listed

### Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

### Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import and Export : Not listed

### Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

### Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

### Regulations of Ozone Depleting Substances Management

List of Controlled Ozone Depleting Substances Import and Export : Not listed

List of Controlled Ozone Depleting Substances : Not listed

### Environmental Protection Law

List of Priority Controlled Chemicals : Not listed

List of Key Controlled New Pollutants : Not listed

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 16. OTHER INFORMATION

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

Revision Date : 2025/04/14

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

### Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Letermovir Liquid Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2024/09/28
3.0	2025/04/14	66856-00023	Date of first issue: 2015/02/27

---

to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN